


EGFR



● EGFR inhibitors

Discovery	Cat.No.	Product Name	Information	Clinical Trial
1997	S1023	Erlotinib HCl (OSI-744)	Targets IC ₅₀ (nM) 2 EGFR	Phase 2
2005	S1025	Gefitinib (ZD1839)	Targets IC ₅₀ (nM) 37 Tyr1173 (NR6wtEGFR cells) Tyr992 (NR6wtEGFR cells) Tyr1173 (NR6W cells) Tyr1173 (NR6W cells) 37 26 57	Phase 3
2008	S1011	Afatinib (BIBW2992)	Targets IC ₅₀ (nM) 0.5 EGFR ^{wt} 0.4 EGFR ^{L858R} 10 EGFR ^{L858R/T790M} HER2 14	Phase 3
2008	S2111	Lapatinib	Targets IC ₅₀ (nM) 10.8 EGFR 9.2 ErbB2	Phase 3
2009	S1173	WZ4002	Targets IC ₅₀ (nM) 2 EGFR ^{L858R} 8 EGFR ^{L858R/T790M}	
2009	S1028	Lapatinib Ditosylate	Targets IC ₅₀ (nM) 10.8 EGFR 9.2 ErbB2	Phase 2
2004	S2150	Neratinib (HKI-272)	Targets IC ₅₀ (nM) 92 EGFR 59 HER2	Phase 2
2007	S2727	Dacomitinib	Targets IC ₅₀ (nM) 6 EGFR ErbB2 45.7 ErbB4 73.7	Phase 2
1991	S1143	AG-490	Targets IC ₅₀ (μM) 0.1 EGFR ErbB2 13.5 JAK2 ~10	
1989	S8009	AG-18	Targets IC ₅₀ (μM) 35 EGFR	
1998	S7039	PD168393	Targets IC ₅₀ (nM) 0.7 EGFR	